Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.IMUX · Entity 6306 | Chief Executive Officer | May 22, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date May 22, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2036-05-22 | Direct | 1,000,000 |
Reported balance
After 2026-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares underlying the options awarded to the Reporting Person will vest on May 22, 2027, and the remaining seventy-five percent (75%) vesting on a monthly basis in thirty-six (36) equal installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. The Reporting Person became a director and a Section 16 insider on June 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares underlying the options awarded to the Reporting Person will vest on May 22, 2027, and the remaining seventy-five percent (75%) vesting on a monthly basis in thirty-six (36) equal installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. The Reporting Person became a director and a Section 16 insider on June 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed Jun 1, 2026 21:57 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 1,000,000 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001193805-26-000731 · e665512_4-lundgren.xml · derivative · entry 1 Lundgren Erik · CIK 0002137540 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2036-05-22 F1 · derivative.exercise_date: The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares underlying the options awarded to the Reporting Person will vest on May 22, 2027, and the remaining seventy-five percent (75%) vesting on a monthly basis in thirty-six (36) equal installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. The Reporting Person became a director and a Section 16 insider on June 1, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.